NOSTRUM LABS
GenericsNOSTRUM LABS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Dermatology.
NOSTRUM LABS's Key Drugs
NOSTRUM LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NOSTRUM LABS's Recent FDA Approvals
New NDA/BLA approvals for NOSTRUM LABS over the last two years — novel drugs only, excluding generics and label supplements.
NOSTRUM LABS's Therapeutic Areas
NOSTRUM LABS's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOSTRUM LABS's Top Competitors
NOSTRUM LABS's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOSTRUM LABS Pipeline Snapshot
Active clinical trials for NOSTRUM LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1993-05-28
- Latest
- 2011-09-20
- Applications
- 8